Fahrer group

Fahrer Group - Immunology

We are working on a very simple and inexpensive cancer immunotherapy treatment, and a bioinformatics study looking for novel proteins in different genomes.

About

The Group is focused on two main areas of research at the moment:

  1. A very simple and inexpensive cancer immunotherapy treatment I have come up with, involving a single injection of an immune stimulant into a tumour.
  2. A bioinformatics study looking for novel proteins in different genomes. We have just recently around 2000 novel proteins from humans and mice.

Publications

Selected publications

Almonte AA, Cavic GC, Carroll SE, Neeman T & Fahrer AM. (2023) Early T cell infiltration correlates with anti-CTLA4 treatment response in murine cancer models. Journal of Immunology. https://doi.org/10.4049/jimmunol.210.Supp.172.02

  • Almonte, A, Cavic, G, Neeman, T, Enders, A, Fahrer, A.M. (2022) Gut microbiome-depleting antibiotic regimens are not tolerated by all mouse strains: learn from (our) bitter experience, Journal for ImmunoTherapy of Cancer, Volume 10, Issue 11.
  • Carroll, C, Andrew, E, Malik, L et al. (2021), Simple and effective bacterial-based intratumoral cancer immunotherapy, Journal for ImmunoTherapy of Cancer, vol. 9, no. 9.
  • Almonte, A, Rangarajan, H, Yip, D et al. (2020) How does the gut microbiome influence immune checkpoint blockade therapy?, Immunology and Cell Biology, 99: 361–372.
  • Wang, J, Gross, G, Andrew, E et al. (2019) A predicted novel protein isoform of HOXA9, Leukemia Research, 82:7-10.
  • Carroll, C, Altin, J, Neeman, T et al. (2015) Repeated fine-needle aspiration of solid tumours in mice allows the identification of multiple infiltrating immune cell types, Journal of Immunological Methods, 425:102-107.
  • Wilson L.O., Spriggs A, Taylor J.M., Fahrer A.M. (2014) A novel splicing outcome reveals more than 2000 new mammalian protein isoforms.Bioinformatics. Jan 15;30(2):151-6
  • Wilson, L.O; Fahrer, A.M. (2013) Condensins, chromatin remodeling and gene transcription, Chromatin Remodelling, Dr Danuta Radzioch (Ed.), ISBN: 978-953-51-1087-3 InTech. Also available from InTech Open
  • Fahrer, Aude M, (2012). A proposal for a simple and inexpensive therapeutic cancer vaccine, Immunology and Cell Biology 90 (3) 310-313
  • Theodoratos, Angelo; Wilson, Laurence O. W.; Gosling, Katharine M.; et al. (2012) Splice variants of the condensin II gene Ncaph2 include alternative reading frame translations of exon 1, Febs Journal 279 (8) 1422-1432
  • Theodoratos, A; Whittle, B; Enders, A; et al. (2010), Mouse strains with point mutations in TAP1 and TAP2, Immunology and Cell Biology 88 (1) 72-78
  • Gosling, KM; Goodnow, CC; Verma, NK; et al (2008), Defective T-cell function leading to reduced antibody production in a kleisin-beta mutant mouse, Immunology 125 (2) 208-217
  • Gosling, KM; Makaroff, LE; Theodoratos, A; et al (2007) A mutation in a chromosome condensin II subunit, kleisin beta, specifically disrupts T cell development, Proceedings of the National Academy Of Sciences of the United States Of America 104 (30) 12445-12450
  • Liston, A; Lesage, S; Gray, DHD; et al, (2004) Generalized resistance to thymic deletion in the NOD mouse: A polygenic trait characterized by defective induction of Bim, Immunity 21 (6) 817-830
  • Fahrer, AM; Bazan, JF; Papathanasiou, P; et al (2001) A genomic view of immunology, Nature 409 (6822) 836-838
  • Fahrer, AM; Konigshofer, Y; Kerr, EM; et al,(2001) Attributes of gamma delta intraepithelial lymphocytes as suggested by their transcriptional profile, Proceedings of the National Academy Of Sciences of the United States Of America 98 (18) 10261-10266.

All publications

Projects

The nessy mouse has a mutation which prevents normal development of T cells. The mutation affects a protein (kleisin beta) involved in chromosome structure. This is an unexpected finding which links two exciting fields of research.

Theme

Infection and immunity

Status

Current

People

Dr Fahrer has published a hypothesis paper suggesting a new method of treating tumours, using an old and inexpensive preparation, that could be of considerable benefit to patients and their cancer management.

Theme

Infection and immunity

Student intake

Open for Honours, PhD students

Status

Current

People

Student intake

Open for Bachelor, PhD students

Status

Current

People

Members

Group Leader

PhD Student

Honours Student

Honorary Lecturer

Divisional Visitor

Volunteer

News

A low-cost, non-toxic cancer treatment has been developed by researchers at The Australian National University (ANU). The treatment uses dead bacteria to help kick-start the immune system and shrink cancer.

Read the article

Aude Fahrer's work aims to activate the immune cells responsible for attacking cancer, in a simple, low cost way.

Read the article